Habio Bioengineering Co., Ltd

Habio Bioengineering Co., Ltd was established in ***2 and has more than **0 employees. It is a manufacturing operation in the industrial Garden of South Suburb in Mianyang, Sichuan. Subordinations include Sichuan Guangyao Bioengineering Co., Ltd and Mianyang Habio Bioengineering Co., Ltd. Habios main products are Phytase, Xylanase, Mannanase, Glucanase, Compound enzyme and some other fermentable products. Our company provides high-quality products and integrated service to more than *0 countries and territories. Relying on the abundant independent R&D ability, powerful manufacture supply capability and the high-quality products, Habio occupies an important position on the field of feed enzyme preparation in China. During the past four years, Habio had invested over *0 Million RMB to build a large scale laboratory with Sichuan University, which engaged in the research of molecular biology, enzyme engineering, microbial fermentation and etc. The company has established Habio Beijing R&D Center in the Feed Research Institue of Chinese Academy of Agricultural Sciences, and has developed strategic partnership with many well-known academic organizations such as Feed Research Institute of Chinese Academy of Agricultural Sciences, Institute of Microbiology of Chinese Academy of Sciences, Tsinghua University, Chinese Science and Technology University, Shanghai Jiao Tong University and Sichuan Agricultural University. Mianyang production base (1st phase) is finished in ***6 covering *2 Acres with total investment *0 Million RMB. Perfectly equipment, advanced technology and numerous products speed up the development of Habio. We have over****0MT fermentation capability per year. Habio has established the integrated Quality Control System, which ensures to provide **0% high-grade products. The company has passed ISO***1 and in process of applying the authentication of HACCP, FAMI-QS, and GMP. As a result, Habio will achieve steady, balanced growth in the future in order to meet the global sales demand, and to become a first-rate biotech company in the world.